Cholesterol metabolism and aggressive prostate cancer: clarifying the signal from EPICAP

By integrating clinical outcomes with biological insight, Cordina-Duverger and colleagues contribute to a discussion that is becoming increasingly structured: the role of cholesterol metabolism—and specifically statin therapy—across prostate cancer (1). Over the years, the relationship between statins and prostate cancer outcomes has generated both enthusiasm and caution, with observational data often preceding definitive mechanistic or prospective confirmation. As our understanding of prostate cancer biology deepens—particularly its reliance on androgen signaling, membrane organization, and metabolic reprogramming—the cholesterol pathway has emerged as a biologically plausible contributor to disease behavior.

With this context, the EPICAP study provides important population-based evidence regarding the relationship between antilipemic therapy and prostate cancer risk, with particular emphasis on tumor grade. In this case-control study including 819 incident cases and 879 controls, the authors report no association between overall antilipemic drug use and prostate cancer incidence. However, a consistent inverse association emerged for statin use—particularly lipophilic statins—and high-grade prostate cancer [International Society of Urological Pathology (ISUP) ≥4], with the strongest effect observed among long-term users (≥10 years).

This distinction between overall incidence and aggressive disease is critical. While overall statin exposure did not significantly modify prostate cancer risk [odds ratio (OR) 0.94; 95% confidence interval (CI): 0.74–1.20], lipophilic statin use was associated with a substantially lower risk of very high-grade tumors (OR 0.30; 95% CI: 0.12–0.77) (1).

Duration further refined this association: use ≥10 years was inversely associated with overall prostate cancer and even more strongly with high-grade disease (1).

Rather than suggesting a chemopreventive effect on tumor initiation, EPICAP reinforces the hypothesis that cholesterol-modulating therapy may preferentially influence biologically aggressive phenotypes.

It is within this biological framework that the findings acquire coherence. Cholesterol metabolism is increasingly recognized as intertwined with prostate cancer biology (2). Cholesterol contributes to intratumoral steroidogenesis, membrane organization through lipid rafts, and activation of signaling pathways such as PI3K/AKT and androgen receptor-mediated cascades (3,4). Inhibition of HMG-CoA reductase by statins disrupts the mevalonate pathway, reducing cholesterol synthesis and downstream isoprenoid intermediates required for protein prenylation (5). Lipophilic statins, by virtue of their passive diffusion into extrahepatic tissues, may exert more direct intraprostatic effects than hydrophilic agents. EPICAP’s stronger associations with lipophilic statins therefore align with plausible pharmacologic and biologic mechanisms rather than representing a random subclass observation (6,7).

Importantly, EPICAP strengthens the epidemiologic signal through methodological rigor. Cases were histologically confirmed and stratified by ISUP grade. Controls were population-based and quota-matched for age and socioeconomic status. Exposure was assessed in detail over the lifetime, enabling duration-response analyses rarely available in registry-based cohorts (1).

In the pre-diagnostic and screening phase, the concept of “statin status” as a chemopreventive factor remains provocative but contentious. A meta-analysis encompassing 21 studies reported no significant association between hydrophilic statins and prostate cancer incidence, whereas lipophilic statins, particularly simvastatin, were associated with a modest but statistically significant reduction in risk, more evident in Western populations. These findings are biologically coherent and align with tissue-penetration hypotheses. Moreover, the suggestion of time-dependent associations, where longer exposure confers greater risk reduction, strengthens the argument for a true biological effect rather than mere confounding (7). Notably, the authors describe the same duration-response relationship, especially among men with high-risk prostate cancer, adding further weight to this hypothesis (1).

However, any discussion of incidence must grapple with a critical confounder: prostate-specific antigen (PSA) suppression. Multiple studies have demonstrated that chronic statin use reduces PSA levels, decreasing the likelihood of exceeding biopsy thresholds. This raises a legitimate concern that reduced incidence among statin users may, at least in part, reflect detection bias rather than true chemoprevention. In this context, it is noteworthy that the authors did not specifically explore the relationship between PSA levels and cancer incidence within their cohort. No stratified analyses were performed according to baseline or mean PSA values across statin users and non-users, nor was there a comparison between hydrophilic and lipophilic statins in relation to PSA distribution and biopsy-driven diagnosis. Such analyses could have helped clarify whether the observed reduction in incidence reflects a biological effect or, at least in part, differences in PSA dynamics and subsequent diagnostic pathways (8,9).

Lower PSA levels could theoretically delay diagnosis, potentially increasing the risk of presenting with advanced disease. Yet paradoxically, observational studies often demonstrate reduced risk of advanced or high-grade disease among statin users, even after adjustment for screening intensity (10). This paradox suggests that PSA suppression alone cannot fully explain the observed associations. Still, the possibility of residual detection bias cannot be dismissed. For this reason, while the notion of statins as chemopreventive agents is intellectually appealing, the current evidence base does not support their routine use for primary prevention of prostate cancer.

A particularly intriguing aspect of EPICAP is the observed interaction between statin use and non-steroidal anti-inflammatory drugs (NSAID) exposure, with inverse associations confined to NSAID users (1).

While exploratory, this finding raises the possibility of synergistic modulation of inflammatory and metabolic pathways, an area deserving mechanistic investigation.

NSAIDs have also attracted attention for their potential anticancer effects, largely due to their ability to modulate inflammatory pathways that are increasingly recognized as contributors to prostate carcinogenesis. Experimental data suggest that both statins and NSAIDs may inhibit tumor growth through pro-apoptotic mechanisms, raising the hypothesis that their combined use could exert additive or synergistic anticancer effects (11).

In this context, several epidemiological studies have attempted to evaluate the joint impact of these agents using standardized exposure definitions rather than simple ever/never categorizations. For example, one study defined regular NSAID use as intake at least four times per week for a minimum of three consecutive months beginning at least 12 months before hospital admission, with statin exposure defined in the same way, allowing the investigators to assess overlapping statin/NSAID use for at least three months. Using this approach, the authors did not observe a protective effect of statin use, alone or combined with NSAIDs, on the risk of advanced prostate cancer (12). In contrast, in the California Men’s Health Study cohort, regular NSAID use was defined as self-reported use of any NSAID for at least 3–4 days per week during the three months preceding the questionnaire or more than 100 prescription days dispensed before baseline. In that analysis, long-term statin use was associated with a reduced risk of prostate cancer only among regular NSAID users [relative risk (RR) 0.64], whereas no association was observed among never or episodic NSAID users (13).

Taken together, these findings illustrate the contradictory nature of the available evidence and underscore the importance of evaluating NSAID exposure using standardized and detailed definitions. Such an approach may be essential to disentangle potential interactions between statins, NSAIDs, and prostate cancer risk, an aspect that remains insufficiently explored when exposure is classified simply as ever versus never use.

Clinically, these findings do not justify prescribing statins for primary prostate cancer prevention in men without cardiovascular indications. However, they refine the ongoing debate. The signal is not one of universal risk reduction but of selective association with aggressive disease, strengthened by duration and lipophilicity. This nuance is essential in an era increasingly focused on distinguishing indolent from clinically significant prostate cancer.

The next step for the field is not premature adoption, nor dismissal. Rather, it is the design of prospective, biomarker-informed studies capable of testing whether cholesterol pathway modulation truly alters the natural history of aggressive prostate cancer. EPICAP study does not close the debate, but it meaningfully sharpens the question.

Supplementary

The article’s supplementary files as

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.